CClinicalTrials.gg
CompletedNCT00565006Updated Feb 27, 2015

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

A Phase 1 interventional study of MK0859 in Ambulatory Blood Pressure, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-27.

Sponsored by Merck Sharp & Dohme LLC · Phase 1 and Interventional

Phase
Phase 1
Study type
Interventional
Enrollment
22
Ages
45 Years to 75 Years
Sex
All
01

Study summary

This study will investigate the influence of MK0859 on ambulatory blood pressure, and how safe and tolerable MK0859 is on the subjects This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

02

Conditions studied

  • Ambulatory Blood Pressure
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,111 studies on the registry; 130 are open to participants now.

Of its 488 completed or terminated interventional studies of FDA-regulated products, 361 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • You are between the ages of 45-75
  • You are a man or non-pregnant woman
  • You agree to not eat or drink fruit or fruit juices (orange, apple or grapefruit) for 2 weeks before starting study medication

Exclusion criteria

Exclusion Criteria:

  • You have smoked or used other nicotine-containing products (chewing tobacco) within the last 6 months
  • You have used St. John's Wort or any products that include it within the last 2 weeks
  • You have used herbal, organic, dietary or nutritional remedies within the last 2 weeks
  • You have a history of drug allergies (anaphylaxis, angioedema)
  • You have taken an investigational drug in another clinical trial within the last 4 weeks
  • You have a history of cardiovascular disease including hypertension (high blood pressure)
  • You have a history of renal disease
  • You have a history of gall bladder disease or have had abnormal liver function tests
  • You have a history of drug or alcohol abuse
  • You drink more than 6 cups of caffeinated beverages a day (coffee, tea or cola)
05

Study design

Phase
Phase 1
Enrollment
22 participants (actual)

Interventions

  • DrugMK0859
06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007 Dec 8;370(9603):1907-14. doi: 10.1016/S0140-6736(07)61813-3. PubMed 18068514 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00565006
Lead sponsor
Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Nov 29, 2007
Start date
Jul 2006
Primary completion
Sep 2006
Completion
Sep 2006
Last update
Feb 27, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion